Seek medical advice before use
When choosing among them, factors such as glycemic efficacy, weight effects and patient preferences may take precedence over concerns about major differences in [GI] risk. She added clinicians should continue to monitor for GI symptoms, particularly early in treatment, as these events, while uncommon, remain more frequent than with some other diabetes drug classes. According to Alkabbani and colleagues, recent trials revealed that dulaglutide (Trulicity, Eli Lilly), semaglutide (Ozempic/Wegovy, Novo Nordisk) and tirzepatide (Zepbound, Eli Lilly) increased the risk for mild to serious GI adverse events like pancreatitis, constipation, nausea, vomiting and biliary disease
It is engineered to maintain temperature for long enough to cover the expected shipping time plus a safety margin
The reconstitution calculator helps determine exact volumes when working with lyophilized peptides that require mixing